

CADTH DRUG REIMBURSEMENT REVIEW

Pharmacoeconomic Report

PEMBROLIZUMAB (KEYTRUDA)

(Merck Canada)

Indication:

For the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression [Combined Positive Score (CPS) ≥ 1] as determined by a validated test.

For the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in combination with platinum and fluorouracil (FU) chemotherapy, in adult patients.

Version: Final

Publication Date: December 22, 2020

Report Length: 16 Pages

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Table of Contents

List of Tables	4
Abbreviations	5
Executive Summary	6
Conclusions	8
Stakeholder Input Relevant to the Economic Review	9
Economic Review	10
Appendix 1: Cost Comparison Table	11
Appendix 2: Submission Quality	12
Appendix 3: Additional Information on the Submitted Economic Evaluation	13
Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation	14
Appendix 5: Submitted BIA and CADTH Appraisal	15

List of Tables

Table 1: Submitted for Review.....	6
Table 2: Summary of Economic Evaluation.....	7

Abbreviations

5-FU	platinum and fluorouracil
CPS	Combined Positive Score
CDR	CADTH Common Drug Review
fpNMA	fractional polynomial Network Meta-Analysis
HNSCC	head and neck squamous cell carcinoma
ICER	incremental cost effectiveness ratio
LY	life year
OS	overall survival
QALY	quality adjusted life year
R/M	metastatic or unresectable recurrent
SOC	standard of care

Executive Summary

The executive summary is comprised of two tables (Table 1: Background and Table 2: Economic Evaluation) and a conclusion.

Table 1: Submitted for Review

Item	Description
Drug product	Pembrolizumab (Keytruda), 100 mg vial
Submitted price	Pembrolizumab, 100 mg vial: \$4,400
Indication	<p>(i) For the first-line (1L) treatment of metastatic or unresectable recurrent (R/M) head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression [Combined Positive Score (CPS) \geq 1] as determined by a validated test.</p> <p>(ii) For the 1L treatment of R/M HNSCC in combination with platinum and fluorouracil (5-FU) chemotherapy, in all adult patients.</p>
Health Canada approval status	NOC
Health Canada review pathway	Standard
NOC date	October 09, 2020
Reimbursement request	As per indication
Sponsor	Merck Canada Inc.
Submission history	<p>Previously reviewed: Yes</p> <p>Pembrolizumab (Keytruda) has been reviewed for multiple indications at CADTH. The following indications were reviewed in 2020.</p> <p>Indication: for the treatment of patients with advanced renal cell carcinoma Recommendation date: April 2, 2020 Recommendation: recommended on the condition of cost-effectiveness being improved to an acceptable level.</p> <p>Indication: for the treatment of patients with metastatic squamous NSCLC Recommendation date: January 3, 2020 Recommendation: recommended on the condition of cost-effectiveness being improved to an acceptable level.</p>

NOC = Notice of Compliance

Table 2: Summary of Economic Evaluation

Component	Description
Type of economic evaluation	Cost-utility analysis Partitioned survival model
Target populations	<i>Monotherapy:</i> Adult patients with R/M HNSCC whose tumours have PD-L1 expression (CPS \geq 1) <i>Combination therapy:</i> All adult patients with R/M HNSCC
Treatments	<i>Monotherapy:</i> Pembrolizumab given alone (monotherapy) <i>Combination therapy:</i> Pembrolizumab + platinum (cisplatin/carboplatin) + 5-FU (combination therapy)
Comparators	<ul style="list-style-type: none"> Platinum + 5-FU Extreme regimen: cetuximab + platinum + 5-FU
Perspective	Canadian publicly funded health care payer
Outcomes	QALYs, LYs
Time horizon	15 years
Key data sources	KEYNOTE-048 trial and sponsor submitted fractional polynomial network meta-analysis (fpNMA) modelling relative efficacy of platinum + 5-FU to pembrolizumab
Submitted results for base case	<i>Monotherapy:</i> ICER = \$68,875 per QALY vs platinum + 5-FU (Δ C = \$68,744, Δ E = 0.9981 QALYs). Extreme regimen extendedly dominated. <i>Combination therapy:</i> ICER = \$91,726 per QALY vs platinum + 5-FU (Δ C = \$92,075, Δ E = 1.0038 QALYs). Extreme regimen extendedly dominated.
Key limitations	<ul style="list-style-type: none"> The Extreme regimen is not a relevant comparator from a Canadian public health payer perspective, since cetuximab is not funded for this indication by participating plans. The sponsor's preferred approach for extrapolating OS beyond the KEYNOTE-048 study resulted in an unrealistic number of patients still alive beyond 10 years. The sponsor's base case analysis included no treatment effect waning. The sponsor overestimated the number of patients receiving subsequent treatment. The sponsor assumed that some patients would receive cetuximab as subsequent treatment following pembrolizumab. Since cetuximab is not funded in Canada for this indication, other (less expensive) subsequent treatments would be provided in Canadian clinical practice. The sponsor's submitted Excel model was excessively complex. This reduced model transparency and made the task of validation difficult. Therefore, CADTH could not guarantee the model was free from error.
CADTH reanalysis results	<ul style="list-style-type: none"> CADTH's reanalysis included the following changes: Extreme regimen removed as a comparator; exponential function used to extrapolate OS; 5-year treatment effect waning applied; number of patients receiving subsequent treatment reduced by 30%; and, subsequent treatment with cetuximab reallocated to platinum + 5-FU following treatment with pembrolizumab. CADTH base case results: <i>Monotherapy:</i> ICER = \$131,260 per QALY vs platinum + 5-FU (ΔC = \$72,550, ΔE = 0.5527 QALYs) (1.9% of iterations below \$50,000 per QALY) <i>Combination therapy:</i> ICER = \$162,165 per QALY vs platinum + 5-FU (ΔC = \$95,650, ΔE = 0.5898 QALYs) (0.6% of iterations below \$50,000 per QALY) For monotherapy and combination therapy an approximate price reduction of 49% and 67% respectively would be required to fall below a WTP threshold of \$50,000 per QALY.

5-FU = platinum and fluorouracil, ICER = incremental cost-effectiveness ratio; LY = life-year; PSM = partitioned survival model; QALY= quality-adjusted life-year

Conclusions

CADTH undertook reanalyses to address several key limitations of the sponsor's model. CADTH's base case reanalysis included a more plausible extrapolation for long term OS, a consideration of 5 -year treatment effect waning, and a lower proportion of patients receiving subsequent treatment more closely aligned with that expected in Canadian practice. These corrections increased the ICER of pembrolizumab compared to the relevant comparator: platinum + 5-FU.

According to CADTH's reanalyses, the ICER for pembrolizumab monotherapy vs platinum + 5-FU in adult patients with R/M HNSCC whose tumours have PD-L1 expression (CPS \geq 1) is \$131,260 per QALY; while the ICER for pembrolizumab combination therapy vs platinum + 5-FU in all adult patients with R/M HNSCC is \$162,165 per QALY. At a WTP threshold of \$50,000 per QALY, a price reduction of 49% is required for pembrolizumab monotherapy to be cost-effective, while a price reduction of 67% is required for pembrolizumab combination therapy to be cost-effective.

It is important to note that CADTH was unable to address limitations stemming from the excessive complexity of the sponsor's model. As such, CADTH was unable to validate calculations in the model, and it is possible that further limitations exist beyond those identified, which may result in an underestimation of the true ICER for pembrolizumab.

Based on the sponsor's submitted BIA, the total incremental cost for reimbursement of pembrolizumab for R/M HNSCC is estimated to be [REDACTED] over three years. CADTH reanalysis suggests that the budget impact of introducing pembrolizumab to the market is underestimated, with the 3-year budget impact from the CADTH base case estimated at \$151,370,606. *(Non-disclosable information was used in this CADTH Guidance Report and the sponsor requested this economic information not be disclosed pursuant to the Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review. This information will remain redacted until notification by the sponsor that it can be publicly disclosed)*

Stakeholder Input Relevant to the Economic Review

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Economic Review

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 1: Cost Comparison Table

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 2: Submission Quality

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 3: Additional Information on the Submitted Economic Evaluation

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 5: Submitted BIA and CADTH Appraisal

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

References

1. Pharmacoeconomic evaluation. In: pan-Canadian Oncology Drug Review sponsor submission: Keytruda (pembrolizumab) powder for solution for infusion 50 mg, solution for infusion 100 mg/4 mL vial. Kirkland (QC): Merck Canada. 2020.
2. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa (ON): CADTH; 2017: <https://www.cadth.ca/dv/guidelines-economic-evaluation-health-technologies-canada-4th-edition>. Accessed 2020 Oct 7.
3. Burtness B, Harrington K, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *The Lancet*. 2019;394:1915-1928.
4. Grunwald V, Chirovsky D, Cheung WY, et al. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results of the GLANCE H&N study. *Oral Oncol*. 2020;102:104526.
5. DeltaPA. [Ottawa (ON)]: IQVIA; 2020: <https://www.iqvia.com/>. Accessed 2020 Oct 7.
6. Keytruda® Budget Impact Analysis report [internal sponsor's report]. 2020.
7. ^{Pf}Carboplatin injection BP: 10 mg/mL (50 mg, 150 mg, 450 mg, 600 mg of carboplatin per vial) [product monograph]. Kirkland (QC): Pfizer Canada ULC; 2019 Dec 16: https://pdf.hres.ca/dpd_pm/00054389.PDF. Accessed 2020 Oct 7.
8. ^{Pf}Cisplatin injection: sterile solution 1 mg/mL (10 mg, 50 mg, 100 mg cisplatin per vial) [product monograph]. Toronto (ON): Teva Canada Ltd; 2016 Oct 31: https://pdf.hres.ca/dpd_pm/00036984.PDF. Accessed 2020 Oct 7.
9. ^{Pf}Fluorouracil injection USP: 50 mg/mL (0.5 g/10 mL and 5g/100 mL) [product monograph]. St. Catharines (ON): Biolyse Pharma Corp; 2018 Mar 7: https://pdf.hres.ca/dpd_pm/00044186.PDF. Accessed 2020 Oct 7.
10. ^{Pf}Paclitaxel: solution for injection, 6 mg/mL [product monograph]. Kirkland (QC): Pfizer Canada ULC; 2020 May 6: https://pdf.hres.ca/dpd_pm/00056371.PDF. Accessed 2020 Oct 7.
11. ^{Pf}Erbix® (cetuximab): Intravenous Injection, 2 mg cetuximab / mL, 50 mL and 100 mL vials [product monograph]. Branchburg (NJ): ImClone LLC; 2018 Jan 10: https://pdf.hres.ca/dpd_pm/00043071.PDF. Accessed 2020 Oct 7.